KRRO Stock Forecast & Price Target

Korro Bio is attractive because its RNA-editing platform is showing early clinical validation, with the first cohort dosed in KRRO-121’s Phase 1/2 ANCHOR study and a first-in-class mechanism aimed at a clear hyperammonemia benchmark of reducing blood ammonia below 200 μmol/L. The program’s disease-agnostic, late-pathway rescue approach could broaden use across urea cycle disorders and other causes of hyperammonemia, while the company’s pipeline momentum is reinforced by a regulatory filing expected in 2H26 and an AATD development candidate nomination in 2Q26. The ASGCT data also strengthen the investment case, as GalNAc delivery produced >70% SERPINA1 editing, ~90% M-AAT protein in vivo, and repeat dosing achieved >90% editing, supporting technical de-risking.

Korro Bio is viewed negatively because its recent PIPE financing diluted equity holders and forced a reset of expectations, even as the balance sheet improved to $157.1M in cash and marketable securities at 3/31/26 from $85.2M at YE25. Collaboration revenue fell to $0 from a derived ~$1.3M in 4Q25 after the Novo Nordisk collaboration pause, while R&D rose to $12.9M and G&A to $7.5M, signaling continued cash burn without offsetting commercial progress. Although the net loss improved to $19.6M from a derived ~$50.0M in 4Q25, that comparison was inflated by prior non-cash impairment and restructuring charges, leaving the core fundamental concern centered on dilution, reliance on external funding, and uncertain revenue traction.